today, the A share market is showing a rebound trend. Baijiu led the big consumer sector to rise and led the Shanghai stock index to stand at 3200 points.
In contrast, there is significant internal differentiation in the pharmaceutical sector. On the one hand, the epidemic situation outside China is still severe, which promotes the continuous warming of anti epidemic themes. The shares of covid-19 testing, covid-19 drugs and other related companies rose sharply
On the other hand, a news about HPV vaccine released by the World Health Organization (who) suddenly fermented, and the shares of related concept stocks fell.
In terms of news, the press conference on epidemic prevention and control in Jilin Province announced that from to 14, Jilin Province will achieve the goal of clearing the social aspects of epidemic prevention and control
For the future, many fund managers said that they should wait and see the specific situation of RRR reduction and policy combination. It is clear that the policy bottom has been further consolidated, and the market bottom may be getting closer and closer.
more than 3000 stocks rose! Market rebound driven by expected RRR reduction
driven by the expectation of interest rate cut, the activity of A-share market increased greatly on the 14th. As of the closing on the 14th, both the Shanghai Composite Index and the Shenzhen Composite Index rose by more than 1.2%, the gem index fell slightly by 0.02%, and more than 3000 stocks rose, led by real estate, covid-19 treatment and testing and other sectors
Many fund managers said that the market has given a good response to the expectation of interest rate reduction. Next, we should wait and see the specific situation of RRR reduction and policy combination. It is clear that the policy bottom has been further consolidated, and the market bottom may be getting closer and closer.
"On April 8, we proposed that the probability of reducing the reserve requirement and interest rate this month is high. The national regular meeting proposed that the reduction of the reserve requirement exceeded the market expectation and met the expectation."
After hours, a large public fund told reporters that on April 13, the national Standing Committee mentioned "timely use of reserve requirement reduction and other monetary policy tools". According to historical experience, the central bank will usually implement the RRR reduction policy 2-30 days after the national Standing Committee proposes the RRR reduction. It is expected that the RRR reduction policy will be implemented in the next 2-3 days. The central bank will also carry out MLF operation on Friday. It is expected that the interest rate reduction policy may appear together at that time, and the subsequent reduction of LPR interest rate is also worth looking forward to.
hpv is on the hot search, and the market value of the leading vaccine has evaporated by 180 billion! The pharmaceutical sector is divided and soared by 1400% in Andon Health Co.Ltd(002432) 5 months
Today, the A share market is rebounding. Baijiu, a liquor maker, has been a big consumer sector and has led the Shanghai stock index to a 3200 point mark. In contrast, there was significant internal differentiation in the pharmaceutical sector, and some vaccine stocks made a deep correction under the disturbance of the news, making the gem index relatively depressed.
The internal differentiation trend of the pharmaceutical sector has triggered heated discussion. On the one hand, the epidemic situation outside China is still severe, promoting the continuous warming of anti epidemic themes, and the shares of covid-19 testing, covid-19 drugs and other related companies rose sharply. Leading gainer Andon Health Co.Ltd(002432) once again blocked the limit, and the share price set a new record, with a cumulative increase of 14 times in the past five months.
On the other hand, a news about HPV vaccine released by the World Health Organization (who) suddenly fermented. The meeting of the WHO Expert Group on immunization strategy (SAGE) believes that a single dose of HPV vaccine also has a reliable protective effect on the virus causing cervical cancer, and the immune effect is equivalent to two doses of vaccine.
The news triggered a lot of discussion, and HPV once ranked first in microblog hot search. In the market, the share prices of several leading vaccine companies fell sharply under the influence of the news.
Andon Health Co.Ltd(002432) new high
5 months soared 1400%
Andon Health Co.Ltd(002432) is undoubtedly the absolute leader in the theme of this round of anti epidemic. Today's intraday trading, Andon Health Co.Ltd(002432) share price once again blocked the limit, and the latest price was reported at 90.11 yuan / share, another record high.
since the low point in November last year, Andon Health Co.Ltd(002432) has increased by more than 1400% in the past five months
Andon Health Co.Ltd(002432) the soaring share price is related to the continuous high volume of covid-19 antigen detection kits exported overseas by the company. Before trading on April 12, Andon Health Co.Ltd(002432) disclosed the performance forecast for the first quarter of 2022. In the first quarter of this year, the net profit attributable to the parent company is expected to reach 14 billion yuan to 16 billion yuan, a year-on-year increase of 3670743% to 4196563%.
Andon Health Co.Ltd(002432) said that affected by the development of the epidemic in the United States, the local demand for covid-19 antigen detection kit products increased significantly. During the reporting period, the US subsidiary of the company sold ihealth covid-19 antigen detection kit products through its own channels and Amazon platform, and signed major contracts and orders with customers. The increase in sales revenue of this product has made an important contribution to the company's performance during the reporting period.
Insiders said that although there are many enterprises engaged in antigen reagents in China, the top performance of Andon Health Co.Ltd(002432) is closely related to the company's development strategy.
On the one hand, Andon Health Co.Ltd(002432) relying on the local business of its U.S. subsidiary, it has obtained the scarce EUA authorization from the U.S. Food and Drug Administration (FDA) Andon Health Co.Ltd(002432) executives once said in a survey in February this year that there are only 13 covid-19 antigen detection kit companies authorized by FDA and EUA;
On the other hand, Andon Health Co.Ltd(002432) has excellent local channel marketing in the United States. The American subsidiary of the company has long been engaged in household testing products and is proficient in online marketing. According to public information, Andon Health Co.Ltd(002432) subsidiary also sponsored the 56th "super bowl" in the United States and distributed 120000 ihealth covid-19 antigen rapid detection kits to fans watching the "super bowl" competition.
However, with the rising share price, the trading risk behind Andon Health Co.Ltd(002432) cannot be ignored.
After hours on April 13, Andon Health Co.Ltd(002432) disclosed the announcement of transaction changes, revealing six risks of the company. Including the risk of uncertainty in the development of the epidemic in the United States, the risk of market competition, the risk that the company's share price and P / E ratio are relatively high, the risk of exchange rate fluctuation, the risk of product quality and the buyer's risk of untimely payment.
Andon Health Co.Ltd(002432) company level prompts multiple transaction risks
Andon Health Co.Ltd(002432) continued to rise the limit, boosting the whole anti epidemic sector.
As of today's closing, the wind covid-19 antigen detection index rose by 5.63%, with Andon Health Co.Ltd(002432) , Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) rising by the limit, and Guangzhou Wondfo Biotech Co.Ltd(300482) , Beijing Hotgen Biotech Co.Ltd(688068) rising by more than 10%; The wind covid-19 specific drug index rose 2.24%, with Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) , Jinghua Pharmaceutical Group Co.Ltd(002349) and Staidson(Beijing) Biopharmaceuticals Co.Ltd(300204) rising by more than 9%.
Covid-19 antigen detection and covid-19 specific drug concept ranking
can hpv vaccine be inoculated in a single dose
vaccine leading company's share price plummeted
On the other side of the continued strength of anti epidemic themes, vaccine stocks belonging to the same pharmaceutical sector suffered a sharp decline today.
as of the closing, the wind vaccine index fell 1.11% against the trend, and the overall market value of the sector evaporated about 47 billion yuan. Industry leader Chongqing Zhifei Biological Products Co.Ltd(300122) plunged 14.19%, and the market value of the company shrank to 185.6 billion yuan; Another 100 billion market value vaccine enterprise Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) fell 9.46%
This is mainly related to an HPV article published by the World Health Organization (who).
HPV, the Chinese name is human papillomavirus. 99.7% of cervical cancer cases are related to HPV infection.
In recent years, the news that one shot of HPV vaccine is difficult to obtain has repeatedly appeared on the hot search. One of the important reasons is that from the perspective of the HPV vaccine immunization procedures that have been approved for listing, two or three doses are basically used for vaccination, and there is no single dose vaccination.
According to an article published on the official website of the who recently, it held an immunization strategy expert group (SAGE) meeting from April 4 to 7 to consider the evidence of one dose of human papillomavirus (HPV) vaccination.
Sage considered that a single dose of HPV vaccine also has a reliable protective effect on cervical cancer virus, and the immune effect is equivalent to that of a single dose of human papillomavirus (HPV) vaccine deliveries solid protection against HPV, the virus that causes cervical cancer, that is comparable to 2-dose schedules.
according to the reporter, most of the HPV vaccine products of Chongqing Zhifei Biological Products Co.Ltd(300122) or Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) are sold in three doses at present
Intercepted from WHO website
In the WHO article, it is also recommended to update the HPV dose plan: give priority to one or two doses of vaccination plan for girls aged 9-14; Provide one or two doses of vaccination plan for young girls aged 15-20; Provide 2 doses of vaccination plan for women over the age of 21, with an interval of 6 months.
Statistics show that Chongqing Zhifei Biological Products Co.Ltd(300122) since signing the supply, distribution and joint promotion agreement of tetravalent HPV vaccine with MSD in September 2012, with the listing and sales of tetravalent and nine valent HPV vaccines, the company's profit volume and roe level have increased rapidly since 2016.
Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) this afternoon, the company made an emergency response by announcing that it was concerned about the public information on the WHO website. The company's products are vaccine products approved and registered by the State Food and drug administration under the demonstration of a large number of clinical studies and data. Women aged 9-45 take three doses (women aged 9-14 can take two doses), and the competitive products mosadon and GSK take all three doses.
Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) disclosure statement announcement at noon today
Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) said that before the change of national policy, the company will continue to sell according to the currently approved doses, but it does not rule out that who and China will actively promote the one dose or two dose immunization procedure in the future. If the existing manufacturers and new entrants obtain the registration license through clinical trials and registration changes, and promote the once or twice dose immunization program in China or abroad, it will have a great impact on the market supply and immunization of the whole cervical cancer vaccine.
from the perspective of stretching dimension, the financial sentiment of A-share vaccine sector has remained low since the second half of last year Chongqing Zhifei Biological Products Co.Ltd(300122) latest share price was 116 yuan / share, which was almost "halved" compared with the high of 230.54 yuan / share in May last year; The latest share price of Cansino Biologics Inc(688185) Kechuang board vaccine company retreated more than 70% from last year's high
Chen Tielin, an analyst at deppon securities, said that since 2020, covid-19 pneumonia has swept the world. With covid-19 vaccines coming on the market one after another outside China, the global wave of covid-19 vaccination has started, but it also has a certain impact on the vaccination of conventional vaccines. In the long run, the squeeze of covid-19 vaccine on conventional vaccination will gradually weaken, and it is optimistic about the recovery of conventional vaccination in the future.
what do you think of the future
The head of the research department of a fund company said there was no doubt about the necessity of reducing the standard. "At present, the triple pressure is still on, and the new challenge lies in the soaring global commodities, the possible acceleration of the pace of interest rate hike by the Federal Reserve, the local outbreak of the epidemic in China, and greater pressure on growth and employment. The meeting of the Financial Committee on March 16 called for monetary policy to take the initiative to respond, and the national Standing Committee on April 6 called for more effective support for the development of the real economy. At the same time, March to April is the peak construction season and the peak of credit supply, and the liquidity consumption is expected to increase, which is the key to reduce the standard Key window period. "
"In order to achieve the annual economic growth target of 5.5%, monetary easing needs to be further strengthened." The official said that at present, the economy is facing multiple pressures mainly from real estate deleveraging and the escalation of the epidemic. The RRR reduction is helpful to stabilize expectations, but it still needs other direct relief and countercyclical policies, including interest rate cuts.
\u3000\u3000 "This round of steady growth policy faces a series of potential constraints from the deleveraging 'soft landing' of real estate, the clearing of hidden liabilities and fiscal sustainability of local governments, the zeroing policy, the determination not to speculate in housing and housing, and the tightening of monetary policy in developed economies. The conclusion of the analysis of various constraints is that monetary easing may be the path of policy easing with the least resistance. The reduction of reserve requirements transmits the signal of steady growth and helps to stabilize expectations, but it is necessary to really stabilize expectations Other direct rescue policies will be reinforced as soon as possible. " The person in charge interpreted.
Huaxia Fund believes that at present, overseas, the market expects the Federal Reserve to raise interest rates about 9 times a year. At the same time, the probability of raising interest rates by 50bp at the May meeting is more than 70%. The narrowing of China US interest rate spread will not restrict the direction of China's monetary policy easing, but will restrict the extent of easing. In China, relying solely on infrastructure and state-owned enterprise investment may not be enough to support the economic growth of the whole year. The further relaxation of real estate policy needs to be set by the highest level. In terms of time point, the Politburo meeting in April is a predictable time point.
Based on April, in terms of equity asset allocation, Huaxia Fund believes that there are four important questions to be answered:
russia and Ukraine—— Continue to track and dilute the impact in the medium and long term.
what about real estate—— It is still in the period of excess return expansion, but the space is limited (10% excess space)
cycle—— The high price can continue, and cyclical stocks are the direction of both reverse investment and boom investment
growth—— The boom will remain the main source of income for the whole year
Huaxia Fund said that in terms of medium - and short-term allocation, the cycle and growth still deserve attention. In terms of cycle, it is optimistic about non-ferrous metals, steel, coking coal and chemical industry, followed by real estate; In terms of growth, we continue to be optimistic about new energy vehicles, semiconductors, photovoltaic and so on.
In addition, many fund managers believe that stabilizing consumption is another focus of this national standing committee meeting. In the future, with the gradual improvement of the epidemic, consumption may become a new breakthrough point in the capital market.
Wu Yue, director of large consumption research of Harvest Fund, believes that the current market is still in a period of wandering at the bottom, and there has not been a comprehensive reversal yet. If there is a comprehensive reversal, we must see the full realization of the steady growth policy, the gradual lifting of external uncertainty, and the transmission of upstream pressure of PPI to downstream CCI. I believe that the second quarter may be a transitional quarter, It may be clearer in the second half of this year.
Wu Yue stressed that from the perspective of the future, this year may be the time when investors need to closely observe the consumption track. There may be structural opportunities from the second quarter. From the second half of this year, there may be a relatively more optimistic and even comprehensive market in the overall consumption sector.
"So at this time point, we don't need to panic or be pessimistic. On the contrary, at this time point, whether from the medium-term dimension or the long-term dimension of two or three years, I think we have reached a window period of focusing on and even starting to increase the layout."
In the consumption field, Yinhua Fund is especially optimistic about baijiu. Yinhua Fund believes that the main reason is that the industry companies are good and the market sentiment has been improved. The previous fall has also accumulated some kinetic energy. We hope that the high-end liquor with pricing power and performance certainty will continue to upgrade, and the Baijiu and Su Baijiu leading by the reform will be upgraded, and the second high-end liquor that is still in the stage of national expansion. Meanwhile, it is expected that the leading Baijiu enterprises are expected to increase in volume and price. After the performance of the leading companies is fulfilled, the valuation of the high-end liquor is expected to be further repaired.
Jimin crazy consultation "bottom copy"! The financial assistant sent out tens of thousands of reminders...
Since this year, the fund has repeatedly boarded the hot search in the sharp decline! However, this year, when the investment fund experience declined, "bottom reading" unexpectedly became a hot word for investor consultation on ant Wealth Financial Assistant "Zhi Xiaobao" in the first quarter, and the amount of consultation increased significantly month on month!
What's going on?
"bottom reading" becomes a hot word for "zhixiaobao" financial consulting
The equity market has fluctuated sharply this year, and there was a rare sharp decline in March. Wind data showed that in the first quarter, the Shanghai stock index fell by more than 10%, and the partial stock fund index fell by more than 17%.
Half the sea, half the fire. While some investors are in panic, others are committed to "bottom reading" or are on the way to "bottom reading".
Ant wealth data show that in the first quarter, among the questions actively consulted by investors to the platform financial assistant "Zhi Xiaobao", the "bottom reading" has become a hot word for consultation, and the number of occurrences is 2.4 times that of the fourth quarter of last year!
In fact, in the first ten days of March this year, Tiantian fund and ant wealth disclosed that at that time, the equity funds on these platforms showed a net subscription trend in recent months. At the same time, the users of yingmi investment consulting service platform "wait a minute" also continued to maintain a net inflow in recent months, and the net inflow rate exceeded the inflow rate when the market was high. On the whole, Jimin did have the behavior of "bottom reading".
For the hot consultation of "bottom reading", the financial assistant "Zhi Xiaobao" has issued tens of thousands of rational reminders to remind investors that it is difficult to grasp the trading time of funds and should not blindly follow the trend. They should know more about the situation of fund products and reduce the operation of chasing up and killing down.
Advisory Reply of ant Wealth Financial Assistant "Zhi Xiaobao" on bottom reading
Good buy fund people believe that it is undeniable that there are players who are naturally sensitive to investment in the market, but such people are very few after all. For the vast majority of investors, it is extremely difficult to try to master the rise and fall laws of the market and individual stocks through their own efforts, so as to achieve accurate timing. With good luck, they may succeed in timing several times in a row, but in the long run, it is the same as the probability of guessing points on the dice.
Microblog investor message
"There are always people who try to avoid every sharp drop and accurately copy the bottom and escape the top, but it is not easy. At present, the market valuation level is relatively undervalued. If you prolong the investment time of the fund, you may get a better investment experience." Insiders said.
